Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy
Open Access
- 24 August 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 5 (1), 1-3
- https://doi.org/10.1038/s41392-020-00254-z
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Immuno-oncology drug development goes globalNature Reviews Drug Discovery, 2019
- PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of CancerCancers, 2019
- Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodiesProtein & Cell, 2016
- Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapyCell Research, 2016
- Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralizationNature Biotechnology, 2010